Consolidative mediastinal irradiation of malignant lymphoma using active scanning proton beams: clinical outcome and dosimetric comparison.
Konsolidierende mediastinale Bestrahlung maligner Lymphome mittels aktivem Rasterscanning mit Protonenstrahlen: Klinische Ergebnisse und dosimetrischer Vergleich.
Adolescent
Adult
Female
Follow-Up Studies
Hodgkin Disease
/ pathology
Humans
Lymphoma, Non-Hodgkin
/ pathology
Male
Mediastinal Neoplasms
/ radiotherapy
Middle Aged
Neoplasm Staging
Organs at Risk
/ radiation effects
Proton Therapy
/ methods
Radiometry
/ methods
Radiotherapy, Intensity-Modulated
/ methods
Treatment Outcome
Young Adult
Intensity modulated radiotherapy
Mediastinal lymphoma
Proton therapy
Radiotherapy
Secondary malignancies
Toxicity
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
05
10
2018
accepted:
25
03
2019
pubmed:
12
4
2019
medline:
15
1
2020
entrez:
12
4
2019
Statut:
ppublish
Résumé
Current research approaches in lymphoma focus on reduction of therapy-associated long-term side effects. Especially in mediastinal lymphoma, proton beam radiotherapy (PT) may be a promising approach for reducing the dose to organs at risk (OAR). In total, 20 patients were irradiated with active scanning PT at Heidelberg Ion Beam Therapy Center (HIT) between September 2014 and February 2017. For comparative analysis, additional photon irradiation plans with helical intensity-modulated radiotherapy (IMRT) were calculated and quantitative and qualitative dose evaluations were made for both treatment modalities. Toxicity and survival outcomes were evaluated. Clinical target volume coverage was comparable in both treatment modalities and did not significantly differ between IMRT and PT. Nevertheless, PT showed superiority regarding the homogeneity index (HI A significant reduction in the dose to the surrounding OAR was achieved with PT compared with photon irradiation, without compromising target volume coverage. Dosimetric advantages may have the potential to translate into a reduction of long-term radiation-induced toxicity in young patients with malignant lymphoma of the mediastinum.
Identifiants
pubmed: 30972453
doi: 10.1007/s00066-019-01460-7
pii: 10.1007/s00066-019-01460-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
677-687Références
Radiat Res. 2000 Oct;154(4):382-8
pubmed: 11023601
Phys Med Biol. 2000 Nov;45(11):3299-317
pubmed: 11098905
Phys Med Biol. 2000 Nov;45(11):3319-30
pubmed: 11098906
Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):244-51
pubmed: 12007965
Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):198-206
pubmed: 15850922
Radiother Oncol. 2004 Dec;73 Suppl 2:S80-5
pubmed: 15971316
Phys Med Biol. 2005 Sep 21;50(18):4337-53
pubmed: 16148397
Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):218-26
pubmed: 16169675
Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):1-7
pubmed: 16618572
N Engl J Med. 2006 Oct 12;355(15):1572-82
pubmed: 17035650
Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1594; author reply 1595
pubmed: 17126218
J Clin Oncol. 2007 Feb 10;25(5):579-86
pubmed: 17242396
Radiother Oncol. 2008 Aug;88(2):202-10
pubmed: 18555548
J Clin Oncol. 2009 Sep 10;27(26):4239-46
pubmed: 19667275
J Clin Oncol. 2010 Mar 10;28(8):1308-15
pubmed: 20142603
Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22
pubmed: 2032882
N Engl J Med. 2010 Aug 12;363(7):640-52
pubmed: 20818855
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e667-71
pubmed: 21459527
Lancet Oncol. 2011 Oct;12(11):1013-22
pubmed: 21940214
J Clin Oncol. 2011 Nov 10;29(32):4234-42
pubmed: 21990399
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):260-7
pubmed: 22014950
J Clin Oncol. 2012 Mar 20;30(9):907-13
pubmed: 22271480
Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):449-55
pubmed: 22386373
Lancet. 2012 May 12;379(9828):1791-9
pubmed: 22480758
J Med Phys. 2012 Oct;37(4):207-13
pubmed: 23293452
Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):46-52
pubmed: 23778197
Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):854-62
pubmed: 23790512
J Clin Oncol. 2013 Nov 10;31(32):4115-22
pubmed: 24062391
Circulation. 2013 Oct 22;128(17):1927-95
pubmed: 24081971
J Clin Oncol. 2014 Apr 10;32(11):1112-8
pubmed: 24493716
Comput Methods Programs Biomed. 2014 Apr;114(2):206-17
pubmed: 24629596
Pediatr Blood Cancer. 2014 Apr;61(4):717-22
pubmed: 24660228
Int J Radiat Oncol Biol Phys. 2014 May 1;89(1):49-58
pubmed: 24725689
Int J Radiat Oncol Biol Phys. 2014 May 1;89(1):175-81
pubmed: 24725700
Radiat Oncol. 2014 Apr 15;9:94
pubmed: 24735767
J Clin Oncol. 2014 Jul 20;32(21):2217-23
pubmed: 24752044
Phys Med Biol. 2014 May 21;59(10):2457-68
pubmed: 24778349
Front Oncol. 2015 Oct 21;5:235
pubmed: 26557501
J Clin Oncol. 2016 Jan 20;34(3):235-43
pubmed: 26573075
N Engl J Med. 2015 Dec 24;373(26):2499-511
pubmed: 26699166
Ann Intern Med. 2016 Jan 19;164(2):93-101
pubmed: 26747086
J Clin Oncol. 2016 May 1;34(13):1443-7
pubmed: 26903576
Acta Oncol. 2016 Sep - Oct;55(9-10):1132-1138
pubmed: 27332881
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):323-330
pubmed: 27913498
Blood. 2017 Apr 20;129(16):2257-2265
pubmed: 28143884
Strahlenther Onkol. 2017 Dec;193(12):1014-1023
pubmed: 28748453
Int J Radiat Oncol Biol Phys. 1993 Dec 1;27(5):1231-9
pubmed: 8262852